Compare Novavax Inc (NVAX) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Quantum Computing Inc — how do they compare? Novavax Inc trades at $12.6 (market cap $1.82B), while Quantum Computing Inc trades at $7.39 (market cap $1.69B). The key difference: Novavax Inc and Quantum Computing Inc are close in size by market cap, and Novavax Inc is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Quantum Computing Inc for 25 Days on average.
| NVAX | QUBT | |
|---|---|---|
Market Cap | $1.82B | $1.69B |
Volume | 6,198,505 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $12.56 | $21.78 |
52-Week Low | $6.22 | $6.31 |
Typical Hold Time | 59 Days | 25 Days |
Enterprise Value | $1.39B | $753.24M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
QUBT trades at $7.39, down 3.02% today, amid a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 revenue of $5.6 million (Zacks Investment Research, 2026-09-08) but remains unprofitable with a net income margin of -152.45%. Recent news highlights the launch of Dirac-3S, scaling to 10,000 variables, with first shipments expected in Q4 2026 (PRNewsWire, 2026-10-01).
Analyst consensus is bullish with a $17.33 price target, but the stock faces significant risks from persistent losses, high cash burn, and competitive pressures. Investment appeal hinges on successful commercialization of quantum technology, though profitability remains distant. The company's $42.5 million backlog and liquidity provide some cushion against execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
